Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

OPTATIO

Financiado

Cerrado

OPtimizing TArgets and Therapeutics In high risk and refractOry Multiple Myeloma

Multiple Myeloma (MM) is an incurable disease with rapidly growing prevalence and poor prognosis. Consequently, it is the goal of the OPTATIO consortium to seek out novel strategies for the development of novel diagnostic and ther... ver más

31/03/2015

MUI

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

MEDIZINISCHE UNIVERSITAT INNSBRUCK No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 10 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2015-03-31 No tenemos la información de la convocatoria

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

10 Participantes

MUI

0.00€ | Lider

UNIBA

N.D. | Participante

VICHEM CHEMIE KUTATO KFT

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

EUIN2013-50988 ENTORNOS BIOMIMETICOS PARA LA EVALUACION IN VITRO DE TRATAMI... 16K€ Cerrado

OVER-MYR Overcoming clinical relapse in multiple myeloma by understan... 4M€ Cerrado

SESAHME Spatially rEsolved Single-cell Approaches in Haematologic Ma... 174K€ Cerrado

3DTUMOUR Development of a high throughput microplate based device to... 150K€ Cerrado

ELMUMY Elucidation of risk factors and health determinants associat... 10M€ Cerrado

SENSITIVITYMARKERS Clinical validation of prognostic biomarkers of chemotherapy... 71K€ Cerrado

Líder del proyecto

MEDIZINISCHE UNIVERSITAT INNSBRUCK No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Multiple Myeloma (MM) is an incurable disease with rapidly growing prevalence and poor prognosis. Consequently, it is the goal of the OPTATIO consortium to seek out novel strategies for the development of novel diagnostic and therapeutic options. The MM pathogenesis involves not only genetic changes within the tumour cells but also the emergence of supportive conditions by the bone marrow microenvironment (BMM). To target the essential components of this support system, it is the goal of the project to establish preclinical in vitro and in vivo models of MM that include functionally relevant elements of the BMM. The OPTATIO consortium will therefore analyse clinical data to correlate the presence of particular MM-BMM interactions with the pathogenesis of MM, with its intrinsic therapy resistance as well as with disease relapse due to the development of acquired drug resistance. These correlative data will be validated using autologous MM-BMM co-culture assays and reverse translated into in vitro screening and in vivo models, which will be subsequently used to develop lead compounds that target myeloma cells within their microenvironment. The clinical expertise of several oncological divisions, the research experience of academic laboratories and the pharmaceutical know-how of small and medium sized enterprises as well as biotech industry joined their efforts within the OPTATIO consortium to drive this important development and to ensure translation towards clinical trials. Expected impacts of the project include establishment of better diagnostics, new drug screening approaches for MM and novel personalised therapies based on individual ex vivo phenotyping leading to reduced patient mortality. Since envisaged drug screening methods are applicable to other areas of research and development, the project results will open new markets for industry partners in the fields of drug discovery and pharmaceutical development of products and services for personalized medicine.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores